1,166 results on '"Burks, A. Wesley"'
Search Results
2. Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study
3. Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial
4. Longitudinal dynamics of the gut microbiome and metabolome in peanut allergy development
5. List Of Contributors
6. Content and Performance of the MiniMUGA Genotyping Array: A New Tool To Improve Rigor and Reproducibility in Mouse Research
7. Peanut-Specific IgG4 and IgA in Saliva Are Modulated by Peanut Oral Immunotherapy
8. Food Allergy and Gastrointestinal Syndromes
9. Contributors
10. Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy
11. Effect of Pre-existing Atopic Disease on Pediatric Peanut Sublingual Immunotherapy (SLIT) Outcomes
12. Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study
13. Irradiated Tree Nut Flours for Use in Oral Immunotherapy
14. Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial
15. Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization
16. Genetic diversity between mouse strains allows identification of the CC027/GeniUnc strain as an orally reactive model of peanut allergy
17. The Consortium for Food Allergy Research (CoFAR): The first generation
18. A mutation inThemiscontributes to peanut-induced oral anaphylaxis in CC027 mice
19. IgE producers in the gut expand the gut’s role in food allergy
20. Phenotypic Characterization of Eosinophilic Esophagitis in a Large Multicenter Patient Population from the Consortium for Food Allergy Research
21. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial
22. Peptide and Recombinant Allergen Vaccines for Food Allergy
23. Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
24. Food allergen extracts to diagnose food-induced allergic diseases: How they are made
25. Preparation and Analysis of Peanut Flour Used in Oral Immunotherapy Clinical Trials
26. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective
27. A Novel Allergen-Specific Immune Signature-Directed Approach to Dietary Elimination in Eosinophilic Esophagitis
28. The latest on food allergy immunotherapy
29. Active treatment for food allergy
30. Characterization of the B-cell receptor repertoires in peanut allergic subjects undergoing oral immunotherapy
31. Efficacy and Safety of Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in Subjects Aged 1-3 Years With and Without Concomitant Food Allergies in the EPITOPE Study
32. Efficacy and Safety of Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in Subjects Aged 1-3 Years With and Without Atopic Dermatitis in the EPITOPE Study
33. Open-label study of the efficacy, safety and durability of peanut sublingual immunotherapy in peanut-allergic children
34. Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy
35. Impact of Allergic Reactions on Food-Specific IgE Concentrations and Skin Test Results
36. International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics
37. International consensus on allergy immunotherapy
38. Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial
39. Targeting CD22 on memory B cells to induce tolerance to peanut allergens
40. Food-specific immunoglobulin A does not correlate with natural tolerance to peanut or egg allergens
41. Intestinal epithelial cell barrier dysfunction and elevated Angiopoietin‐like 4 identified in orally susceptible peanut allergy model
42. Kinetics of basophil hyporesponsiveness during short-course peanut oral immunotherapy
43. Mast cell desensitization inhibits calcium flux and aberrantly remodels actin
44. Oral Tolerance and Eosinophilic Esophagitis
45. Induction of Tolerance for Food-Induced Anaphylaxis
46. Novel peanut-specific human IgE monoclonal antibodies enable screens for inhibitors of the effector phase in food allergy
47. Allergen recognition by specific effector Th2 cells enables IL ‐2‐dependent activation of regulatory T‐cell responses in humans
48. Long-term follow-up of IgE-mediated food allergy: determining persistence versus clinical tolerance
49. The natural history of egg allergy in an observational cohort
50. State of the art on food allergen immunotherapy: Oral, sublingual, and epicutaneous
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.